“`html
The average one-year price target for Lyell Immunopharma (NasdaqGS:LYEL) has been increased to $19.38 per share, representing a 35.71% rise from the previous estimate of $14.28 on November 14, 2025. The updated targets from analysts range from a low of $12.12 to a high of $26.25 per share, indicating a 23.25% decrease from the latest closing price of $25.25 per share.
In the last quarter, 108 funds reported positions in Lyell Immunopharma, a decrease of 48 owners (30.77%). Total institutional shares owned rose by 12.45% to 10,250K shares, with an average portfolio weight of 0.51%, an increase of 247.33%. The put/call ratio is 1.60, suggesting a bearish outlook.
Key institutional holders include Arch Venture with 2,759K shares (13.00% ownership, a 34.01% increase), FSMAX – Fidelity Extended Market Index Fund with 1,025K shares (4.83% ownership, a 4.66% increase), and SCHA – Schwab U.S. Small-Cap ETF with 888K shares (4.18% ownership, a 2.36% decrease).
“`
